Cell plasma membranes represent a crucial barrier for the intracellular translocation of cargoes (e.g., drug and imaging agents) into deeper subcellular organelles. Cell-penetrating peptides (CPPs) technology has become a popular cellular entry strategy in the theranostic diseases, including cancers, rheumatoid arthritis, Alzheimer's, etc. Various cargoes, including small molecules, antibody peptides, proteins, nucleic acids, and nanocarriers, have been successfully transported into cells by CPPs. Based on their physical-chemical properties, CPPs can also be divided into three subgroups: cationic CPPs, amphipathic CPPs, and hydrophobic CPPs. In addition to conventional linear CPPs, cyclic CPPs have displayed more prominent penetrating properties. CPP becomes a potential strategy to overcome many bio-carriers, such as blood-brain barriers, intestinal mucosa, nasal mucosa, and skin barriers. Its application fields are broadening continuously. CPPs can be attached to cargoes by complexing or covalently linking to exert their enhanced pharmacological efficacy.
There has been a growing interest in employing cell-penetrating peptides technology to conquer cell membranes or other bio-barriers for the intracellular entry of various cargoes in the application of therapy and diagnosis of diseases. In this context, we will focus on the design and discovery of new CPPs, transduction mechanism of CPP-cargoes, novel CPPs-based cargo delivery systems, and CPPs-derived barriers-penetrating nanomedicines; pharmacokinetics/pharmacodynamics of CPP-cargoes. These aspects are extremely favorable for the clinical translation of CPP-cargoes. In this Research Topic, we would like to highlight the value of CPPs-based delivery of drugs or imaging agents in extensive diseases and present a basic understanding and advanced progress of CPPs.
We encourage the submissions of original research articles, perspectives, opinion articles, and reviews that focus on, but are not limited to, the following potential topics:
• Design and discovery of new CPPs
• Development and evaluation of novel CPPs-based cargo delivery systems
• Biological properties and biophysics of CPP-cargoes
• Transduction mechanism or kinetics of CPP-cargoes
• Pharmacokinetics/pharmacodynamics of CPP-cargoes
Frontiers in Experimental Pharmacology and Drug Discovery does not accept publication studies carried out with crude extracts or mixtures. Only the use of highly purified, chemically characterized compounds is acceptable.
Whenever a complex mixture is used, data with the single components of the mixture, in precisely defined dose/concentration, should be provided (and/or previously published). This also applies to in silico studies on supposed mechanisms underlying supposed actions of crude extracts and/or mixtures.
Cell plasma membranes represent a crucial barrier for the intracellular translocation of cargoes (e.g., drug and imaging agents) into deeper subcellular organelles. Cell-penetrating peptides (CPPs) technology has become a popular cellular entry strategy in the theranostic diseases, including cancers, rheumatoid arthritis, Alzheimer's, etc. Various cargoes, including small molecules, antibody peptides, proteins, nucleic acids, and nanocarriers, have been successfully transported into cells by CPPs. Based on their physical-chemical properties, CPPs can also be divided into three subgroups: cationic CPPs, amphipathic CPPs, and hydrophobic CPPs. In addition to conventional linear CPPs, cyclic CPPs have displayed more prominent penetrating properties. CPP becomes a potential strategy to overcome many bio-carriers, such as blood-brain barriers, intestinal mucosa, nasal mucosa, and skin barriers. Its application fields are broadening continuously. CPPs can be attached to cargoes by complexing or covalently linking to exert their enhanced pharmacological efficacy.
There has been a growing interest in employing cell-penetrating peptides technology to conquer cell membranes or other bio-barriers for the intracellular entry of various cargoes in the application of therapy and diagnosis of diseases. In this context, we will focus on the design and discovery of new CPPs, transduction mechanism of CPP-cargoes, novel CPPs-based cargo delivery systems, and CPPs-derived barriers-penetrating nanomedicines; pharmacokinetics/pharmacodynamics of CPP-cargoes. These aspects are extremely favorable for the clinical translation of CPP-cargoes. In this Research Topic, we would like to highlight the value of CPPs-based delivery of drugs or imaging agents in extensive diseases and present a basic understanding and advanced progress of CPPs.
We encourage the submissions of original research articles, perspectives, opinion articles, and reviews that focus on, but are not limited to, the following potential topics:
• Design and discovery of new CPPs
• Development and evaluation of novel CPPs-based cargo delivery systems
• Biological properties and biophysics of CPP-cargoes
• Transduction mechanism or kinetics of CPP-cargoes
• Pharmacokinetics/pharmacodynamics of CPP-cargoes
Frontiers in Experimental Pharmacology and Drug Discovery does not accept publication studies carried out with crude extracts or mixtures. Only the use of highly purified, chemically characterized compounds is acceptable.
Whenever a complex mixture is used, data with the single components of the mixture, in precisely defined dose/concentration, should be provided (and/or previously published). This also applies to in silico studies on supposed mechanisms underlying supposed actions of crude extracts and/or mixtures.
